13 June 2016 - The EMA has published an EPAR for Novartis' second brand of sacubitril with valsartan.

The European Commmission approved Neparvis on 26 May 2016 for use in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

Neparvis will be subjected to additional monitoring by the EMA.

For more details, go to: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004343/human_med_001982.jsp&mid=WC0b01ac058001d124